Vivos Therapeutics Inc (VVOS)

$2.22 +0.08 (3.50%)
Market Cap 12.60M
Revenue (ttm) 15.03M
Net Income (ttm) -11.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -74.12%
Debt to Equity Ratio 0.00
Volume 75,496
Avg Vol 106,838
Day's Range N/A - N/A
Shares Out 5.89M
Stochastic %K 25%
Beta 7.02
Analysts Sell
Price Target $4.22

Company Profile

Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children....

Industry: Medical Devices
Sector: Healthcare
Phone: 844 672 4357
Address:
7921 Southpark Plaza, Suite 210, Littleton, United States
Richapeslayer_pounce
Richapeslayer_pounce Jun. 16 at 3:41 PM
$VVOS They are signing up new patients as we speak
0 · Reply
Squeezepepper
Squeezepepper Jun. 16 at 2:53 PM
$VVOS
0 · Reply
PaddyIce87
PaddyIce87 Jun. 16 at 2:47 PM
$VVOS The sentiment has taken a dramatic shift and a lot of good info out as of late. She is looking primed and ready to do what she’s always been meant to do. $6+ and beyond on the near horizon IMO. NFA DYOR
1 · Reply
ACInvestorBlog
ACInvestorBlog Jun. 16 at 2:43 PM
$VVOS Did anyone read this report from WTR ? Opportunity to generate $6M+ in monthly revenue from oral appliance sales. Company has a market cap of $12M The price-to-sales ratio is already below its peers. The potential is HUGE and a takeover candidate imho
0 · Reply
ahab
ahab Jun. 16 at 2:00 PM
$VVOS on the lotto play 4/9/25 candle , shadow 2.00 - 2.25 chute $3
0 · Reply
jeffthechef
jeffthechef Jun. 16 at 4:30 AM
@ACInvestorBlog $VVOS going to make us a lot of money!!
0 · Reply
indepth1
indepth1 Jun. 16 at 3:52 AM
$VVOS @StockFlips @JL_TradeZ @DougieFreshPicks @dbr_island Buy $VVOS in premarket on 6-16 at $2.16 est. ask... Following @ACInvestorBlog excellent DD with details of undervalued VVOS with extrapolation of likely future revenue. 🎯 DD Based in part on✨ ✨ recent SCN acquisition. T/A IMO = Bottoming for reversal up in next few days.💎 Double Bottoming in $VVOS on the 3 month price chart at Barchart.com. Price patterns of $VVOS retesting very year low price again with 3 positive divergences 💎 in indicator charts.✨ ✨ $ZBAI =💎💎 Buy based on DD and T/a from @DancingQueen69 that i followed at $.425 on 6-10 added more on 6-13 based on T/A IMO = Bottomed with reversal up this week. 💎 💎 globenewswire.com/news-rele... ✨ 🎯 Bullish DD on 2 stocks in post & Lucy's timely picks! ATIF Holdings Limited Announces Strategic Diversification to Bitcoin Business✨ 🎯 https://www.globenewswire.com
1 · Reply
indepth1
indepth1 Jun. 16 at 3:07 AM
$VVOS
0 · Reply
rxptgh
rxptgh Jun. 15 at 8:38 AM
$VVOS this has the potential to be a 3-5+ bagger from these levels
1 · Reply
Giovannirs3
Giovannirs3 Jun. 13 at 8:15 PM
$VVOS 👇
0 · Reply
Latest News on VVOS
Vivos Therapeutics, Inc. (VVOS) Q1 2025 Earnings Call Transcript

May 15, 2025, 7:31 PM EDT - 4 weeks ago

Vivos Therapeutics, Inc. (VVOS) Q1 2025 Earnings Call Transcript

Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call

May 14, 2025, 9:15 AM EDT - 4 weeks ago

Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call

Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada

Apr 16, 2025, 8:30 AM EDT - 2 months ago

Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada

Vivos Therapeutics, Inc. (VVOS) Q4 2024 Earnings Call Transcript

Apr 1, 2025, 12:18 AM EDT - 2 months ago

Vivos Therapeutics, Inc. (VVOS) Q4 2024 Earnings Call Transcript

Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update

Mar 31, 2025, 4:20 PM EDT - 2 months ago

Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call

Mar 28, 2025, 8:30 AM EDT - 2 months ago

Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call

Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 23, 2024, 8:00 AM EST - 6 months ago

Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 11:31 PM EST - 7 months ago

Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript

Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call

Nov 13, 2024, 5:00 PM EST - 7 months ago

Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call

Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

Oct 8, 2024, 7:30 AM EDT - 8 months ago

Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

Sep 18, 2024, 7:00 AM EDT - 9 months ago

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

Vivos Therapeutics, Inc. (VVOS) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 2:05 PM EDT - 10 months ago

Vivos Therapeutics, Inc. (VVOS) Q2 2024 Earnings Call Transcript

Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Aug 14, 2024, 4:05 PM EDT - 10 months ago

Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call

Aug 14, 2024, 7:30 AM EDT - 10 months ago

Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call

Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model

Jun 27, 2024, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model

Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance

Jun 12, 2024, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance

Vivos Therapeutics, Inc. (VVOS) Q1 2024 Earnings Call Transcript

May 17, 2024, 9:02 PM EDT - 1 year ago

Vivos Therapeutics, Inc. (VVOS) Q1 2024 Earnings Call Transcript

Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update

May 14, 2024, 4:05 PM EDT - 1 year ago

Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call

May 14, 2024, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call

Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

Apr 9, 2024, 7:30 AM EDT - 1 year ago

Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 11:10 PM EDT - 1 year ago

Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call

Mar 28, 2024, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call

Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities

Feb 6, 2024, 7:30 AM EST - 1 year ago

Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities

Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company's Proprietary Oral Medical Devices to Treat Severe OSA

Jan 8, 2024, 7:30 AM EST - 1 year ago

Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company's Proprietary Oral Medical Devices to Treat Severe OSA

Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”

Dec 11, 2023, 7:30 AM EST - 1 year ago

Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”

Vivos Therapeutics' stock soars as sleep apnea device gets regulatory clearance

Nov 29, 2023, 11:09 AM EST - 1 year ago

Vivos Therapeutics' stock soars as sleep apnea device gets regulatory clearance

US FDA clears Vivos Therapeutics' oral device treatment for sleep apnea

Nov 29, 2023, 7:44 AM EST - 1 year ago

US FDA clears Vivos Therapeutics' oral device treatment for sleep apnea

Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea

Nov 29, 2023, 7:30 AM EST - 1 year ago

Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea

Vivos Therapeutics, Inc. (VVOS) Q3 2023 Earnings Call Transcript

Nov 17, 2023, 7:12 PM EST - 1 year ago

Vivos Therapeutics, Inc. (VVOS) Q3 2023 Earnings Call Transcript

Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update

Nov 14, 2023, 4:05 PM EST - 1 year ago

Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call

Nov 9, 2023, 4:30 PM EST - 1 year ago

Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call

Vivos Therapeutics Closes $4 Million Private Placement

Nov 2, 2023, 5:00 PM EDT - 1 year ago

Vivos Therapeutics Closes $4 Million Private Placement

Vivos Therapeutics Announces Reverse Stock Split

Oct 26, 2023, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Announces Reverse Stock Split

Vivos Therapeutics Signs Nationwide Distribution Agreement with Lincare

Oct 24, 2023, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Signs Nationwide Distribution Agreement with Lincare

Vivos Therapeutics to Begin Clinical Trial at Stanford Medicine

Oct 11, 2023, 7:30 AM EDT - 1 year ago

Vivos Therapeutics to Begin Clinical Trial at Stanford Medicine

Vivos Therapeutics Announces Strategic Collaboration in the Middle East-North Africa Region to Support International Expansion

Oct 5, 2023, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Announces Strategic Collaboration in the Middle East-North Africa Region to Support International Expansion

Vivos Therapeutics Executes Strategic Agreements with Ormco and On Demand Orthodontist To Provide Spark™ Clear Aligners to Its National Network of Providers

Oct 4, 2023, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Executes Strategic Agreements with Ormco and On Demand Orthodontist To Provide Spark™ Clear Aligners to Its National Network of Providers

New York Times Best-Selling Author James Nestor to Headline List of Speakers for Fifth Annual Vivos Breathing Wellness Conference

Oct 2, 2023, 7:30 AM EDT - 1 year ago

New York Times Best-Selling Author James Nestor to Headline List of Speakers for Fifth Annual Vivos Breathing Wellness Conference

Vivos Therapeutics Reports Second Quarter 2023 Financial Results and Provides Operational Update

Aug 16, 2023, 4:05 PM EDT - 1 year ago

Vivos Therapeutics Reports Second Quarter 2023 Financial Results and Provides Operational Update

Vivos Therapeutics Reschedules Second Quarter 2023 Financial Results Conference Call

Aug 16, 2023, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Reschedules Second Quarter 2023 Financial Results Conference Call

Vivos Therapeutics to Reschedule Second Quarter 2023 Financial Results Conference Call

Aug 14, 2023, 5:06 PM EDT - 1 year ago

Vivos Therapeutics to Reschedule Second Quarter 2023 Financial Results Conference Call

Vivos Therapeutics Schedules Release of Second Quarter 2023 Financial Results and Conference Call

Aug 10, 2023, 8:31 PM EDT - 2 years ago

Vivos Therapeutics Schedules Release of Second Quarter 2023 Financial Results and Conference Call

Vivos Therapeutics, Inc. (VVOS) Q1 2023 Earnings Call Transcript

Jun 9, 2023, 12:24 PM EDT - 2 years ago

Vivos Therapeutics, Inc. (VVOS) Q1 2023 Earnings Call Transcript

Vivos Therapeutics Reports First Quarter 2023 Financial Results and Provides Operational Update

Jun 8, 2023, 4:05 PM EDT - 2 years ago

Vivos Therapeutics Reports First Quarter 2023 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of First Quarter 2023 Financial Results and Conference Call

Jun 6, 2023, 4:30 PM EDT - 2 years ago

Vivos Therapeutics Schedules Release of First Quarter 2023 Financial Results and Conference Call

Clinical Study Shows 92% of Patients Report Resolution of Migraine Headaches Using Vivos' POD® Appliance Treatment

May 1, 2023, 7:30 AM EDT - 2 years ago

Clinical Study Shows 92% of Patients Report Resolution of Migraine Headaches Using Vivos' POD® Appliance Treatment

Vivos Therapeutics, Inc. (VVOS) Q4 2022 Earnings Call Transcript

Mar 31, 2023, 6:05 PM EDT - 2 years ago

Vivos Therapeutics, Inc. (VVOS) Q4 2022 Earnings Call Transcript

Vivos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Operational Update

Mar 30, 2023, 4:05 PM EDT - 2 years ago

Vivos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Operational Update

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Conference Call

Mar 30, 2023, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Conference Call

Richapeslayer_pounce
Richapeslayer_pounce Jun. 16 at 3:41 PM
$VVOS They are signing up new patients as we speak
0 · Reply
Squeezepepper
Squeezepepper Jun. 16 at 2:53 PM
$VVOS
0 · Reply
PaddyIce87
PaddyIce87 Jun. 16 at 2:47 PM
$VVOS The sentiment has taken a dramatic shift and a lot of good info out as of late. She is looking primed and ready to do what she’s always been meant to do. $6+ and beyond on the near horizon IMO. NFA DYOR
1 · Reply
ACInvestorBlog
ACInvestorBlog Jun. 16 at 2:43 PM
$VVOS Did anyone read this report from WTR ? Opportunity to generate $6M+ in monthly revenue from oral appliance sales. Company has a market cap of $12M The price-to-sales ratio is already below its peers. The potential is HUGE and a takeover candidate imho
0 · Reply
ahab
ahab Jun. 16 at 2:00 PM
$VVOS on the lotto play 4/9/25 candle , shadow 2.00 - 2.25 chute $3
0 · Reply
jeffthechef
jeffthechef Jun. 16 at 4:30 AM
@ACInvestorBlog $VVOS going to make us a lot of money!!
0 · Reply
indepth1
indepth1 Jun. 16 at 3:52 AM
$VVOS @StockFlips @JL_TradeZ @DougieFreshPicks @dbr_island Buy $VVOS in premarket on 6-16 at $2.16 est. ask... Following @ACInvestorBlog excellent DD with details of undervalued VVOS with extrapolation of likely future revenue. 🎯 DD Based in part on✨ ✨ recent SCN acquisition. T/A IMO = Bottoming for reversal up in next few days.💎 Double Bottoming in $VVOS on the 3 month price chart at Barchart.com. Price patterns of $VVOS retesting very year low price again with 3 positive divergences 💎 in indicator charts.✨ ✨ $ZBAI =💎💎 Buy based on DD and T/a from @DancingQueen69 that i followed at $.425 on 6-10 added more on 6-13 based on T/A IMO = Bottomed with reversal up this week. 💎 💎 globenewswire.com/news-rele... ✨ 🎯 Bullish DD on 2 stocks in post & Lucy's timely picks! ATIF Holdings Limited Announces Strategic Diversification to Bitcoin Business✨ 🎯 https://www.globenewswire.com
1 · Reply
indepth1
indepth1 Jun. 16 at 3:07 AM
$VVOS
0 · Reply
rxptgh
rxptgh Jun. 15 at 8:38 AM
$VVOS this has the potential to be a 3-5+ bagger from these levels
1 · Reply
Giovannirs3
Giovannirs3 Jun. 13 at 8:15 PM
$VVOS 👇
0 · Reply
Mac82
Mac82 Jun. 13 at 8:04 PM
$VVOS Added more today. Been holding long for a while.
0 · Reply
Rounderssss4
Rounderssss4 Jun. 13 at 7:58 PM
$VVOS looking good going into next week
0 · Reply
Rounderssss4
Rounderssss4 Jun. 13 at 7:44 PM
$VVOS price is stupid low where we are
0 · Reply
ACInvestorBlog
ACInvestorBlog Jun. 13 at 7:44 PM
$VVOS TRADING AT BARGAIN PRICES IMHO Im long and strong !! Potential GEM ... i do believe in my next $GRRR 2.0
0 · Reply
Rounderssss4
Rounderssss4 Jun. 13 at 7:43 PM
$VVOS she wants green
0 · Reply
TheRealSixShifty
TheRealSixShifty Jun. 13 at 7:42 PM
$VVOS added again at 2.11
0 · Reply
RamGuy_949322
RamGuy_949322 Jun. 13 at 7:40 PM
$VVOS
0 · Reply
ACInvestorBlog
ACInvestorBlog Jun. 13 at 7:40 PM
$VVOS The market cap of Vivos is just $12M "If Vivos achieves the two-thirds capture rate seen with its Rebis alliance, the SCN revenue opportunity could be more than $6 million per month, assuming an average of $4,500 per case, and with a higher gross margin than Rebis. In addition, SCN has treated more than 200,000 patients, many of which have stopped CPAP or looking for alternative treatments." They can make $6M PER MONTH !!!!!!
0 · Reply
ACInvestorBlog
ACInvestorBlog Jun. 13 at 7:36 PM
$VVOS todays report: TRADING AT BARGAIN PRICES !!! VVOS: SCN Acquisition Closed; Key Step in Strategic Pivot Thats crazy. Just $12 mark cap !!!! "If Vivos achieves the two-thirds capture rate seen with its Rebis alliance, the SCN revenue opportunity could be more than $6 million per month, assuming an average of $4,500 per case, and with a higher gross margin than Rebis. In addition, SCN has treated more than 200,000 patients, many of which have stopped CPAP or looking for alternative treatments."
0 · Reply
Seczet
Seczet Jun. 13 at 7:09 PM
$VVOS in
0 · Reply
Giovannirs3
Giovannirs3 Jun. 13 at 6:39 PM
$VVOS All-time lows for nasdaq scam👇👍
0 · Reply
Giovannirs3
Giovannirs3 Jun. 13 at 3:26 PM
$VVOS 👍❤️
0 · Reply